Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Shares Purchased by Wells Fargo & Company MN

Share on StockTwits

Wells Fargo & Company MN boosted its holdings in Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) by 90.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 96,945 shares of the company’s stock after buying an additional 45,922 shares during the period. Wells Fargo & Company MN owned 0.09% of Eyepoint Pharmaceuticals worth $159,000 at the end of the most recent reporting period.

Separately, Strs Ohio acquired a new stake in Eyepoint Pharmaceuticals in the 2nd quarter worth about $27,000. 58.62% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:EYPT opened at $2.11 on Friday. The company has a current ratio of 5.46, a quick ratio of 5.31 and a debt-to-equity ratio of 1.75. Eyepoint Pharmaceuticals Inc has a one year low of $1.19 and a one year high of $3.78. The business’s 50-day simple moving average is $1.73 and its 200 day simple moving average is $1.64.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyepoint Pharmaceuticals had a negative return on equity of 165.24% and a negative net margin of 621.04%. The business had revenue of $7.21 million for the quarter, compared to the consensus estimate of $6.75 million. On average, analysts expect that Eyepoint Pharmaceuticals Inc will post -0.53 earnings per share for the current year.

A number of analysts have issued reports on the company. B. Riley decreased their price target on Eyepoint Pharmaceuticals from $5.75 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, September 24th. ValuEngine upgraded Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Zacks Investment Research downgraded Eyepoint Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. HC Wainwright restated a “buy” rating and issued a $4.50 price objective on shares of Eyepoint Pharmaceuticals in a report on Wednesday, September 25th. Finally, Guggenheim assumed coverage on Eyepoint Pharmaceuticals in a report on Thursday, September 12th. They issued a “buy” rating and a $4.00 price objective on the stock. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $3.69.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Read More: Market Timing

Institutional Ownership by Quarter for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.